Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Free Cash Flow (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Free Cash Flow for 6 consecutive years, with -$7.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 50.41% to -$7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$39.9 million through Dec 2025, up 34.91% year-over-year, with the annual reading at -$39.9 million for FY2025, 34.91% up from the prior year.
  • Free Cash Flow hit -$7.2 million in Q4 2025 for Bolt Biotherapeutics, up from -$9.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$4.7 million in Q2 2021 to a low of -$24.9 million in Q1 2022.
  • Historically, Free Cash Flow has averaged -$15.4 million across 5 years, with a median of -$15.6 million in 2023.
  • Biggest five-year swings in Free Cash Flow: surged 65.01% in 2021 and later plummeted 330.57% in 2022.
  • Year by year, Free Cash Flow stood at -$17.0 million in 2021, then dropped by 15.75% to -$19.7 million in 2022, then increased by 27.92% to -$14.2 million in 2023, then decreased by 1.5% to -$14.4 million in 2024, then surged by 50.41% to -$7.2 million in 2025.
  • Business Quant data shows Free Cash Flow for BOLT at -$7.2 million in Q4 2025, -$9.8 million in Q3 2025, and -$9.6 million in Q2 2025.